Randomized, Double-Blind Phase 1 Safety and Tolerability Study of Pafuramidine Maleate (DB289) in Healthy Subjects

NCT00619346 ↗

Phase 1 Terminated 100 enrolled Immtech Pharmaceuticals, Inc

RandomizedParallel-groupDouble-blind

Summary

This is a phase 1 study to establish the safety and tolerability profile of pafuramidine maleate 100 mg BID administered orally for 14 days to healthy subjects

Timeline

Start: 2007-11
Primary completion: 2009-02
Completion: 2009-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Pafuramidine	Small molecule	100 mg	Oral

Indications

No indication recorded.